Sequence Variations in the
 FII
 ,
 FV
 ,
 F13A1
 ,
 FGB
 and
 PAI-1
 Genes are Associated with Differences in Myocardial Perfusion

Satra, Maria; Σαμαρά, Μαρία; Wozniak, Greta; Tzavara, Chara; Kontos, Angelos; Valotassiou, Varvara; Vamvakopoulos, Nicholas C.; Tsougos, Ioannis; Aleporou-Marinou, Vassiliki; Patrinos, George P.; Κollia, Panagoula; Georgoulias, Panagiotis

doi:10.2217/pgs.10.180

Cited by 20 publications

(15 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Additionally, an association between this polymorphism and adverse myocardial perfusion was found. 22 In contrast, a protective effect of the mutated A allele against the development of AMI was found, with a higher prevalence of carriers of the mutated A allele in controls than in patients. 41 The Effect of This Polymorphism May Appear in the Mild Disease, UA Not in the Severe IHD, and AMI Combined thrombophilia markers were observed in our study.…”

Section: Discussionmentioning

confidence: 91%

Association of Hemostatic Gene Polymorphisms With Early-Onset Ischemic Heart Disease in Egyptian Patients

Alkhiary

Azzam

Youssef

et al. 2016

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The association between hereditary thrombophilia and venous thrombosis is well established but controversial data exist with respect to arterial thrombosis. We performed a pilot study on 31 patients with acute myocardial infarction (AMI), 21 patients with unstable angina (UA), and 20 healthy volunteers to investigate the role of various hemostatic gene polymorphisms in young Egyptian patients, who survived their first ischemic heart disease (IHD). Thrombophilic gene polymorphisms were tested using multiplex polymerase chain reaction and reverse-hybridization technique. We showed an increased risk of AMI with factor V (FV) Leiden and prothrombin G20210A heterozygosity. The increased risks of UA was associated with GA and A allele of fibrinogen β-455G→A polymorphism. Conversely, factor XIII (FXIII) Val34Leu GT and T allele were protective in the UA group. Nevertheless, the prevalence of FV H1299R, plasminogen activator inhibitor 1 4G/5G, glycoprotein IIIa C1565T, 5,10-methylenetetrahydrofolate reductase C677T, and A1298C mutations did not differ between patients with IHD and controls. The data have clinical implications regarding screening and thromboprophylaxis in high-risk individuals younger than 40 years.

show abstract

Section: Discussionmentioning

confidence: 91%

Association of Hemostatic Gene Polymorphisms With Early-Onset Ischemic Heart Disease in Egyptian Patients

Alkhiary

Azzam

Youssef

et al. 2016

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…However, we believe that a better understanding of CAD development can be achieved through the analysis of genetic information combined with functional imaging. Although Izadpanah et al did not find any association between the rs2713604 polymorphism and premature MI, we have reported the independent correlations (after adjustment for various factors, including CAD risk factors) of several gene polymorphisms with myocardial ischemia, based on stressrest myocardial single-photon emission computed tomography (SPECT) imaging [4][5][6]. In particular, polymorphisms of the following genes were investigated: factor V Leiden, factor II prothrombin, plasminogen activator inhibitor 1, β-fibrinogen, factor XIII, apolipoprotein E, angiotensin l-converting enzyme, angiotensinogen, angiotensin II type 1 receptor, angiotensin II type 2 receptor, and renin.…”

mentioning

confidence: 77%

Novel approaches for the management of coronary artery disease

Angelidis

Valotassiou

Κollia

et al. 2020

Herz

View full text Add to dashboard Cite

“…Не так давно выделена группа так называемых «новых» ФР, к которым прежде всего относят полиморфизмы в генах. Если взаимосвязь факторов окружающей среды и ИБС достаточно хорошо известны, то значение генетических маркеров изучено не в полной мере [5]. Так, например, согласно последним исследованиям наблюдается связь между ИБС и полиморфизмами в генах, кодирующих факторы свертывания крови, ингибиторы тканевого активатора плазминогена I типа (РАI-I), фибринолитические факторы и рецепторы тромбоцитарных мембран [5].…”

Section: Discussionunclassified

“…Если взаимосвязь факторов окружающей среды и ИБС достаточно хорошо известны, то значение генетических маркеров изучено не в полной мере [5]. Так, например, согласно последним исследованиям наблюдается связь между ИБС и полиморфизмами в генах, кодирующих факторы свертывания крови, ингибиторы тканевого активатора плазминогена I типа (РАI-I), фибринолитические факторы и рецепторы тромбоцитарных мембран [5]. Особое внимание среди большого числа генов-кандидатов привлекают полиморфные варианты генов II (FII) и V (FV) факторов свертывания крови, гена, кодирующего метилентетрагидрофолатредуктазу (MTHFR) (особенно его однонуклеотидный полиморфизм С677T), ассоциированные с развитием ССЗ, которые могли являться ФР ОКС.…”

Section: Discussionunclassified

“…Напротив, курильщиков среди пациентов с ОКС оказалось больше (74,5 и 32 % соответственно). Ранее доказано, что курение является одним из самых важных модифицируемых ФР у молодых пациентов с ИМ [5,11]. Средний показатель ИМТ у пациентов с ОКС был выше, чем в группе контроля (29,0±0,52 против 25,96±0,56 кг / м 2 , р=0,001).…”

Section: Discussionunclassified

See 1 more Smart Citation

Thrombosis risk factors and gene mutations in young age patients with acute coronary syndrome

Ponomarenko

Сукманова

2019

Kardiologiia

View full text Add to dashboard Cite

Goal of research. Study the role of thrombosis risk factors and polymorphisms in genes in young age patients with acute coronary syndrome (ACS).Materials and methods. Te study included 299 patients of age 25 to 44 years old with ACS were treated from 2012 to 2017 at the department of myocardial infarction 1st KGBUZ Altay regional cardiological clinic. Te middle age of patients with ACS was 40.3 ± 0.2 years. Te control group included of 53 apparently healthy volunteers aged from 25 to 44 years old, the average age those patients was 39.94 ± 0.79 years. Also, those patients hadn’t any comorbid conditions. Te control group hadn’t any datas of ischemic heart disease by the results of exercise tolerance tests. All patients had standard clinical, anamnestic, biochemical tests, lipid profle, fasting plasma glucose, electrocardiogram, echocardiography and coronaroangiography, also they were determined growth and weight with body-weight index. 116 patients from the ACS group and 53 patients fromthe control group had screening of polymerase chain reaction for determine polymorphism of the FII genes G20210-A, FV G1691-A, and MTHFR C677-T.Results. We identifed the most signifcant sets of risk factors associated with ACS in young age patients based on our multifactorial statistical analysis with binary logistic regression. Tis combination of risk factors was: increased levels of low-density lipoproteins, decreased levels of high-density lipoproteins, smoking, existence of MTHFR homozygous polymorphism, heredity in combination with smoking, FV homozygote, MTHFR homozygote, smoking with MTHFR-homozygote.Conclusion. Te ability predicting the risk of developing cardiovascular disease in young people based on traditional risk factors, partly modifable, as well as the researching of "new" risk factors, opens up new opportunities for developing a clinical approach of treating young patients with high risk of ACS.

show abstract

Sequence Variations in the FII , FV , F13A1 , FGB and PAI-1 Genes are Associated with Differences in Myocardial Perfusion

Cited by 20 publications

References 53 publications

Association of Hemostatic Gene Polymorphisms With Early-Onset Ischemic Heart Disease in Egyptian Patients

Association of Hemostatic Gene Polymorphisms With Early-Onset Ischemic Heart Disease in Egyptian Patients

Novel approaches for the management of coronary artery disease

Thrombosis risk factors and gene mutations in young age patients with acute coronary syndrome

Contact Info

Product

Resources

About